Risk factors for oral methotrexate failure in patients with inflammatory polyarthritis: results from a UK prospective cohort study

BACKGROUND: Oral methotrexate (MTX) is the first-line therapy for patients with rheumatoid arthritis (RA). However, approximately one quarter of patients discontinue MTX within 12 months. MTX failure, defined as MTX cessation or the addition of another anti-rheumatic drug, is usually due adverse eve...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Arthritis Res Ther
Main Authors: Bluett, James, Sergeant, Jamie C., MacGregor, Alex J., Chipping, Jacqueline R., Marshall, Tarnya, Symmons, Deborah P. M., Verstappen, Suzanne M. M.
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2018
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5859656/
https://ncbi.nlm.nih.gov/pubmed/29554956
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-018-1544-9
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki